EU finance for Israeli coronavirus treatment

The European Fund for Strategic Investments (EFSI) advancing Israel’s Pluristem 50 million Euros to fund 50% of its pioneering regenerative PLX cell therapy platform. Pluristem’s treatment has saved six critically ill Israeli coronavirus patients (see previously).

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *